大剂量普通干扰素联合利巴韦林治疗慢性丙型肝炎的疗效

Therapeutic Effect of High-dose Common Interferon Combined With Ribavirin On Chronic Hepatitis C

目的探究在慢性丙型肝炎(CHC)治疗中,应用大剂量普通干扰素α2b联合利巴韦林的效果.方法将80例CHC患者作为本次研究对象,分别对患者实施大剂量普通干扰素α2b联合利巴韦林治疗(观察组)、聚乙二醇化α干扰素联合利巴韦林治疗(对照组);观察其效果和安全性,并实施对比分析.结果观察组患者的HCV RNA转阴率为70.0%,对照组为72.5%,两组HCV RNA转阴率比较,差异无统计学意义(P>0.05);观察组患者脱发、食欲下降不良反应发生率低于对照组,差异具有统计学意义(P<0.05);两组患者的过性发热与皮疹的发生率比较,差异无统计学意义(P>0.05).结论对CHC治疗时应用大剂量普通干扰素α2b联合利巴韦林的效果和常规方法相近,但安全性良好.

Objective To investigate the effect of high dose interferon α2b combined with ribavirin in the treatment of chronic hepatitis C (CHC). Methods 80 patients with CHC were treated with high dose interferon α2b combined with ribavirin (observation group) and pegylated interferon α combined with ribavirin (control group) respectively. The effects and safety were observed, and to carry out comparative analysis. Results The negative rate of HCV RNA was 70.0% in the observation group and 72.5% in the control group. There was no significant difference in the negative rate of HCV RNA between the two groups (P > 0.05). The incidence of hair loss and loss of appetite in the observation group was lower than that in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the incidence of overfever and rash between the two groups (P > 0.05). Conclusion The effect of combined ribavirin and ribavirin in the treatment of CHC is similar to that of ribavirin, but the safety is good and the value of ribavirin is more important.